A future therapeutic strategy undertaking an unbiased screening approach to identify potent SorLA blocking antibodies might provide a way forward in targeting heregulin-driven activation of the HER2-HER3 dimer in breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.